National Institutes of Health's Therapeutics Portfolio

TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.

MAIA Biotechnology is a clinical-stage biopharmaceutical company developing cancer therapies that target telomeres through immunotherapy.

Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases.

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.

Zenflow is a medical company that gives new hope to men suffering from BPH symptoms.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.

Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.

Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.

Envisagenics reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions.

SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.

Integrated BioTherapeutics focuses on the discovery of novel vaccines and therapeutics for emerging infectious diseases.

ProLynx is a biotechnology company that develops proprietary drug-delivery technologies to extend the half-life of therapeutic molecules.

iQure Pharma is a global biotech company that develops new therapeutics for patients and physicians.

Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.

Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.

Lucid Diagnostics develops a non-invasive, office based diagnostic test for biomarkers to esophageal cancer.

Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications for CNS-based disorders.

Lamassu Pharma is a biotech startup that solves the critical unmet medical need for severe acute pancreatitis.

Hepatx is developing regenerative medicine solutions.

Hillhurst develops technologies enabling the therapeutic use of low-dose carbon monoxide.